Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 02 2018 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that on May 1, 2018 the Compensation Committee of
Aclaris’ Board of Directors granted 3 non-qualified stock option
awards to purchase an aggregate of 21,000 shares of its common
stock and 8 restricted stock unit awards covering an aggregate of
17,000 shares of its common stock to 8 new employees under
the Aclaris 2017 Inducement Plan. The stock options and
restricted stock units were granted as inducements material to the
new employees becoming employees of Aclaris in accordance with
NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Aclaris (or following a bona fide period
of non-employment), as an inducement material to such individual's
entering into employment with Aclaris, pursuant to Rule 5635(c)(4)
of the NASDAQ Listing Rules.
The options have an exercise price of $18.07 per share, which is
equal to the closing price of Aclaris' common stock on May 1, 2018.
Each option and restricted stock unit award will vest, and become
exercisable (as applicable), as to twenty-five percent of the
shares on each of the first, second, third and fourth anniversaries
of the recipient's start date, subject to each such employee's
continued employment with Aclaris on such vesting dates. The
options and restricted stock unit awards are subject to the terms
and conditions of Aclaris' 2017 Inducement Plan, and the terms and
conditions of a stock option agreement or restricted stock unit
agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a dermatologist-led biopharmaceutical company
committed to identifying, developing, and commercializing
innovative therapies to address significant unmet needs in
dermatology, both aesthetic and medical, and immunology. Aclaris’
focus on market segments with no FDA-approved medications or where
treatment gaps exist has resulted in the first FDA-approved
treatment for raised seborrheic keratoses and several clinical
programs to develop medications for the potential treatment of
common warts, alopecia areata, and vitiligo. For additional
information, please visit www.aclaristx.com and follow Aclaris
on LinkedIn.
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate
Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024